Business News

Six SARS-CoV-2 Candidate Vaccines in the World Entered Clinical Trial Stages  

Jie  Zhang
Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji, 311800, China
Author    Correspondence author
Journal of Vaccine Research, 2020, Vol. 10, No. 3   
Received: 08 May, 2020    Accepted: 10 May, 2020    Published: 10 May, 2020
© 2020 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

1. Tree Vaccine in China, based on viral vector and being a more traditional type, Entered Clinical Trials

2. Two Vaccine in USA, based on mRNA technology and is designed and modified directly on the messenger ribonucleic acid, different from traditional approaches to vaccine development, Entered Clinical Trials

3. One Vaccine in UK, based on the development of adenovirus vector vaccine and the spike protein of SARS-CoV-2, Entered Clinical Trials

Keywords
SARS-CoV-2; Vaccine; Clinical trial

(The advance publishing of the abstract of this manuscript does not mean final published, the end result whether or not published will depend on the comments of peer reviewers and decision of our editorial board.)
Journal of Vaccine Research
• Volume 10
View Options
. PDF
. HTML
Associated material
. Readers' comments
Other articles by authors
. Jie  Zhang
Related articles
. SARS-CoV-2
. Vaccine
. Clinical trial (The advance publishing of the abstract of this manuscript does not mean final published, the end result whether or not published will depend on the comments of peer reviewers and decision of our editorial board.)
Tools
. Post a comment